Progressive Supranuclear Palsy (PSP) Market Outlook

Thelansis’s “Progressive Supranuclear Palsy (PSP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Supranuclear Palsy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Progressive Supranuclear Palsy (PSP) Overview

Progressive supranuclear palsy (PSP) is a rare, rapidly progressive 4-repeat (4R) tauopathy marked by the abnormal aggregation of hyperphosphorylated tau protein in the basal ganglia, brainstem, and cerebral cortex. This widespread neurodegeneration leads to a profound loss of motor, oculomotor, and cognitive functions. Patients typically present after age sixty with early postural instability causing frequent backward falls, symmetric axial rigidity, dysarthria, dysphagia, and the disease’s pathognomonic sign: vertical supranuclear gaze palsy, which makes downward gaze nearly impossible. Clinically characterized via Richardson’s syndrome or atypical variants, diagnosis is supported by brain MRI showing midbrain atrophy (the “hummingbird sign”). Current standard therapies are strictly symptomatic and highly limited; levodopa offers only minimal, transient benefit for rigidity. Because legacy trials like Amylyx’s AMX0035 (ORION) failed to alter the disease course, the modern therapeutic frontier focuses heavily on targeted, disease-modifying mechanisms. Advanced strategies in 2026 center on Novartis’s NIO752, an intrathecal antisense oligonucleotide designed to directly suppress MAPT mRNA and lower tau production, which entered the large-scale Phase 3 PRESERVE trial. Concurrently, the newly launched NIH-supported PSP Trial Platform (PTP) is pioneering a multi-arm framework simultaneously evaluating novel assets: the tau vaccine AADvac1, the lysosomal tau-clearance enhancer AZP2006 (ezeprogind), and the p75NTR receptor modulator LM11A-31. Early, coordinated intervention within these molecular-targeted networks remains critical to altering the trajectory of this aggressive tauopathy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)